As the largest resource of information specific to women's brain health, we are sure you will find what you are looking for, and promise that you will discover new information.
Published on: March 23, 2012
by Science Codex
An international team of researchers have developed a new method for measurement of aggregated beta-amyloid – a protein complex believed to cause major nerve cell damage and dysfunction in Alzheimer’s disease. The new method might facilitate diagnosis and detection as well as development of drugs directed against aggregated beta-amyloid.
Alzheimer’s disease (AD) is the most common cause of memory decline and dementia. According to the Alzheimer World Report 2011, today around 36 million people suffer from Dementia (around 20 – 25 million are Alzheimer’s patients).
These numbers will dramatically increase with the aging populations over the next few decades. For the year 2050 the expected number of dementia patients will be 115 – 200 million (70 – 150 million Alzheimer’s cases). It is therefore important to develop new therapies and diagnostic methods to detect and treat this complex chronic neurodegenerative brain disease.
Alzheimer’s disease is characterized by aggregates in the brain, containing a protein called beta-amyloid. The neuropathology of Alzheimer’s disease has recently been linked to the neurotoxic amyloid-β (Aβ)
oligomers. The crucial role of Aβ oligomers in the early events of AD is experimentally underlined.
Several recent results suggest that those oligomers may cause the death of neurons and neurological dysfunctions relevant to memory. Furthermore Aβ oligomers levels are increased in brain and cerebrospinal fluid samples from people with Alzheimer’s disease. This reflects the potential of Aβ oligomers as a marker for the early diagnosis of the disease.
An international team of scientists from Germany, Sweden and the U.S. have used a new method to quantify soluble variants of aggregated beta-amyloid (Aβ oligomers) in cerebrospinal fluid by flow cytometry. “We found that patients with a greater number of Aβ oligomers in the cerebrospinal fluid had a more pronounced disease,” says Dr. Alexander Navarrete Santos (the developer of this method and now employee of the Research Laboratory of the University of Halle, Department of Cardiothoracic Surgery), and first author of the study.
He analyzed the cerebrospinal fluid of 30 neurological patients, including 14 Alzheimer’s patients. “These samples provided from leading expert academic memory clinics in Germany and Sweden are of the best quality and are highly characterized in order to provide robust and reliable results on promising novel biomarker candidates”, Professor Harald Hampel of Frankfurt University, a lead investigator comments.
“Because of the limited number of samples, however, further study is needed to confirm the results,” said Dr. Oskar Hansson of Lund University. The study was an international cooperation with the University of California in the U.S., the Goteborg and Malmö Universities from Sweden and the University of Frankfurt in Germany.
The test might not only be used for the early detection of AD but can also be used when developing new and effective therapies for AD. A decline in the number of Aβ oligomers in cerebrospinal fluids could be a hint for the effectiveness of new drug therapies.
For the first time, scientists have produced evidence in living humans that the protein tau, which mars the brain in Alzheimer’s disease, spreads from neuron to neuron. Although such movement wasn’t directly observed, the finding...
When the average person goes to the doctor, shows up at the ER, or enters the hospital, the possibility of controlling what happens next is minimal. We put ourselves...
According to the Alzheimer’s Society of Canada, 72% of Canadians living with Alzheimer’s disease are women. Is that because of their biological sex at birth? Does it have to do with the fact that...
The material presented through the Think Tank feature on this website is in no way intended to replace professional medical care or attention by a qualified practitioner. WBHI strongly advises all questioners and viewers using this feature with health problems to consult a qualified physician, especially before starting any treatment. The materials provided on this website cannot and should not be used as a basis for diagnosis or choice of treatment. The materials are not exhaustive and cannot always respect all the most recent research in all areas of medicine.